1887

Abstract

. causes a wide range of infections, such as endocarditis, pneumonia, osteomyelitis, skin and soft tissue infections, and implant/in-dwelling device-related infections. poses a significant challenge to clinicians because of its ability to rapidly acquire multi-drug resistance and quickly progress into a recurrent, chronic infection by biofilm formation. Levonadifloxacin (WCK 771) is a novel broad-spectrum antibacterial agent (it recently completed a phase 3 trial in India) with a differentiated mechanism of action involving high affinity to staphylococcal DNA gyrase, and is active against multi-drug-resistant (MDR) , including those that are resistant to quinolones. The present study investigated the bactericidal activity of levonadifloxacin against biofilm-embedded clinical isolates in comparison with other anti- drugs.

. The bactericidal activity of levonadifloxacin and comparator drugs such as vancomycin, linezolid and daptomycin was evaluated against planktonic and biofilm-encapsulated recent methicillin- and quinolone-resistant clinical isolates using time–kill, biofilm eradication and scanning electron microscopy analysis.

. Levonadifloxacin displayed a consistent ≥90 % bacterial kill rate against biofilm-embedded organisms, while vancomycin and linezolid displayed variable activity and daptomycin did not show any activity. Scanning electron microscopy images further confirmed the efficacy of levonadifloxacin against biofilm, showing the disruption of biofilm structure and a corresponding reduction in the viable bacterial count.

. These results show that levonadifloxacin has an improved bactericidal effect on biofilm-embedded quinolone-resistant and meticillin-resistant , and that it can be a promising treatment option for such infections.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000999
2019-08-01
2020-01-25
Loading full text...

Full text loading...

References

  1. Lister JL, Horswill AR. Staphylococcus aureus biofilms: recent developments in biofilm dispersal. Front Cell Infect Microbiol 2014;4:178 [CrossRef]
    [Google Scholar]
  2. Patel MV, De Souza NJ, Gupte SV, Jafri MA, Bhagwat SS et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother 2004;48:4754–4761 [CrossRef]
    [Google Scholar]
  3. Correia S, Poeta P, Hébraud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we stand?. J Med Microbiol 2017;66:551–559 [CrossRef]
    [Google Scholar]
  4. Flamm RK, Farrell DJ, Sader HS, Rhomberg PR, Jones RN. In Vitro Activity of WCK 771, a benzoquinolizine fluoroquinolone (levonadifloxacin) when tested against contemporary Gram-positive and -negative bacteria from a global surveillance program ASM Microbe Boston, MA, USA: 2016
    [Google Scholar]
  5. CLSI Performance Standards for Antimicrobial Susceptibility Testing, 28th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
    [Google Scholar]
  6. CLSI Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard - 10th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
    [Google Scholar]
  7. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 1985;22:996–1006
    [Google Scholar]
  8. Chao Y, Zhang T. Optimization of fixation methods for observation of bacterial cell morphology and surface ultrastructures by atomic force microscopy. Appl Microbiol Biotechnol 2011;92:381–392 [CrossRef]
    [Google Scholar]
  9. Bhagwat SS, Mundkur LA, Gupte SV, Patel MV, Khorakiwala HF. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother 2006;50:3568–3579 [CrossRef]
    [Google Scholar]
  10. Betriu C, Redondo M, Boloix A, Gómez M, Culebras E et al. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother 2001;48:911–913 [CrossRef]
    [Google Scholar]
  11. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the leader 2004 surveillance program. Antimicrob Agents Chemother 2005;49:5024–5032 [CrossRef]
    [Google Scholar]
  12. Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew DP. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:1503–1509 [CrossRef]
    [Google Scholar]
  13. Lee DG, Murakami Y, Andes DR, Craig WA. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother 2013;57:1434–1441 [CrossRef]
    [Google Scholar]
  14. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665–4672 [CrossRef]
    [Google Scholar]
  15. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318–1322 [CrossRef]
    [Google Scholar]
  16. Siala W, Mingeot-Leclercq MP, Tulkens PM, Hallin M, Denis O et al. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2014;58:6385–6397 [CrossRef]
    [Google Scholar]
  17. Upadhyay DJ, Patel MV, Agarwal SK, Sreenivas K, Jafri MA et al. WCK 771A - An investigational fluorquinolone (FQ) with unusual property of retaining potency in acidic medium, human urine and efficacy in mouse pyelonephritis model Chicago: ICAAC; 2001
  18. de Souza NJ, Gupte SV, Deshpande PK, Desai VN, Bhawsar SB et al. A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J Med Chem 2005;48:5232–5242 [CrossRef]
    [Google Scholar]
  19. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 2011;55:649–658 [CrossRef]
    [Google Scholar]
  20. Rodvold KA, Gotfried MH, Chugh R, Gupta M, Yeole R et al. Intrapulmonary pharmacokinetics of levonadifloxacinLevonadifloxacin following oral administration of Alalevonadifloxacin to healthy adult subjects. Antimicrob Agents Chemother 2018;62:2302 2018; [CrossRef]
    [Google Scholar]
  21. Martínez SR, Rocca DM, Aiassa V, Becerra MC. Linezolid as an eradication agent against assembled methicillin-resistant Staphylococcus aureus biofilms. RSC Adv 2016;6:101023–101028 [CrossRef]
    [Google Scholar]
  22. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2005;49:2467–2473 [CrossRef]
    [Google Scholar]
  23. Daddi Oubekka S, Briandet R, Fontaine-Aupart MP, Steenkeste K. Correlative time-resolved fluorescence microscopy to assess antibiotic diffusion-reaction in biofilms. Antimicrob Agents Chemother 2012;56:3349–3358 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000999
Loading
/content/journal/jmm/10.1099/jmm.0.000999
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error